Immunogen Profit Margin

Immunogen (IMGN) currently reports a profit margin of -25.41% as of September 2023. That compares with -210.33% in the prior-year period — up 87.9% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Immunogen's profit margin history and peer comparisons.

Immunogen's profit margin increased from -210.33% to -25.41% — a 87.9% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immunogen's profit margin of -25.41% is lower than the Healthcare sector average of 13.89%. That is roughly 282.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Immunogen's current -25.41% should be judged against Healthcare norms (sector average: 13.89%) and against IMGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -25.41%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Immunogen, and consider following IMGN for alerts when major investors trade the stock.